Cerdwen Ventures · Life Sciences Evaluator
"The public should always be wondering how it is possible for a company to give so much for the price it charges." — Henry Ford
Internal VC Tool
Connecting...

AI Pitch Deck Analysis BETA

Upload pitch materials and Claude will auto-fill the evaluation, run market intelligence, and prepare your meeting brief.

📄
Click to upload or drag & drop
PDF, Word, Excel, PowerPoint, PNG, JPG · Multiple files · Max 100MB total
Company Profile
Pipeline status:
Screening
Diligence
IC Review
Invested
Passed

Market Intelligence

Powers TAM calculation and Investment Memo. Enter what you know or let AI estimate.

HighEV Value Dimensions

Score each dimension relative to the incumbent. 5 = massive improvement, 3 = moderate, 1 = minimal or parity.

$
Financial Value
Cost to payer, system, and patient vs. incumbent
—
▼
Cost to payer / patient
How much cheaper vs. current standard? Equal cost for better outcome counts.
3
Same cost or more10× cheaper
Healthcare system savings
Reduces downstream costs — hospitalizations, readmissions, long-term care?
3
No changeMassive downstream savings
Reimbursement / pricing power
Likelihood of payer coverage; ability to command premium vs. generics.
3
Poor coverage likelyHighly reimbursable
⚙
Effort Value
Burden on physician, patient, and care team
—
▼
Physician workflow friction
Special training, new equipment, prior authorization vs. current practice?
3
Major disruptionSeamless adoption
Patient compliance burden
How easy is it for patients to use/adhere vs. incumbent?
3
Much harderMuch easier
Diagnostic / testing requirements
Requires companion diagnostics or complex biomarker testing?
3
Complex Dx neededNo extra testing
⏱
Time Value
Speed-to-benefit, treatment duration, time-to-market
—
▼
Speed-to-benefit for patient
How quickly does the patient see improvement vs. current standard?
3
SlowerDramatically faster
Duration of therapy
One-time cure vs. chronic treatment. Curative scores higher.
3
Chronic, indefiniteOne-time / curative
Regulatory approval timeline
BTD, Orphan, RMAT pathways score higher.
3
10+ yrs standard pathAccelerated pathway
⚠
Risk Value
Clinical, safety, execution and adoption uncertainty
—
▼
Safety profile vs. incumbent
Novel mechanism + small safety DB = physician hesitation 2–5 yrs post-approval.
3
Worse / unknownClearly safer
Clinical evidence strength
Head-to-head P3 RCT data scores highest. Hypothesis only scores lowest.
3
Hypothesis onlyHead-to-head P3 RCT
IP / moat defensibility
Patents, trade secrets, regulatory exclusivity vs. generic / me-too risk.
3
Easily replicatedStrong multi-layer moat
Manufacturing / scalability risk
Complex biologics, cell therapies score harder.
3
Highly complexProven, scalable
✓
Functional Value
Objective clinical outcomes vs. standard of care
—
▼
Absolute clinical benefit magnitude
OS, PFS, HbA1c, pain scores. Relative improvements only count if absolute is meaningful.
3
Marginal / surrogateOrder-of-magnitude better
Unmet need severity
Last-line therapy for fatal disease vs. incremental in well-treated condition?
3
Well-treated conditionNo current options
Addressable patient population
Breadth of patients who qualify. TAM proxy.
3
Ultra-rare (<1K)100M+ globally
◎
Psychological Value
KOL enthusiasm, patient demand, brand, social signaling
—
▼
Physician / KOL enthusiasm
"I need this" vs "interesting" — the most reliable early commercial signal.
3
"Interesting" — indifferent"I need this" — strong pull
Patient demand / advocacy
Will patients seek this out? Patient advocacy tailwinds?
3
Passive marketHigh patient pull
Brand / narrative strength
Being "best practice" is a moat in medicine.
3
Generic / commodityCategory-defining
👤
Founder & Team
Prior exits, clinical ops experience, KOL network, team completeness
—
▼
Prior exits / track record
Has the team built and sold a life sciences company before? Repeat founders reduce execution risk by 40–60%.
3
First-time / academicMultiple successful exits
Clinical operations experience
Can they actually run a trial? IND-to-approval operational depth vs. discovery-only teams.
3
Discovery-only / no opsFull IND-to-NDA team
Domain KOL / network depth
Do the right physicians, payers, and FDA advisors already know and trust this team?
3
Unknown / no networkDeep KOL + FDA relationships
Team completeness
Clinical, regulatory, commercial, and scientific leadership in place vs. key gaps requiring critical hires.
3
Major gaps / solo founderComplete executive team

FDA Approval vs. Adoption Risk Modifier

~20–40% of approved drugs see limited uptake. Approval risk ends at the FDA; market risk starts there.

Adoption Probability Scorecard

The 5 independent adoption filters. Failure in any one can stall uptake regardless of FDA approval.
Estimated adoption probability vs. full potential
—
HighEV Score
—
/ 100
Score your startup
Adjust sliders to calculate
0Cerdwen threshold ▶100

Projected Adoption Trajectory

🏛
Innovators
Academic centers
→
👨‍⚕️
Early Adopters
KOL specialists
→
🏥
Community
Specialty practice
→
🌍
Primary Care
Mass market scale

Market Opportunity

⚠ Investor Red Flags Detected

Investment signal analysis

AI Deal Analyst Claude
Analyzing with Claude...
Intelligence Brief & Meeting Prep Live Data
Fetching ClinicalTrials.gov, FDA, PubMed + synthesizing with Claude...
Competitive Intelligence Brief
Clinical Trial Design Assessment
Meeting Questions

    Partner Notes (saved to shared database)

    Save evaluation first to add notes.
    Deal Pipeline
    Loading pipeline...
    All Evaluations
    Loading evaluations...
    Investment Memo
    No evaluation loaded
    Complete an evaluation, then click Generate Memo.
    "The only repeatable method for building successful companies is delivering massive net value add to customers relative to their current way of solving the same problem." — Kevin Brophy, Cerdwen Ventures
    Framework Overview

    HighEV Core Principle

    We analyzed five centuries of startup success and failure. Companies that win — outside of anomalous speculations — are the ones that massively outperform peers in net value add to customers relative to the current way of solving the same problem.

    FDA Approval ≠ Adoption

    ~20–40% of FDA-approved drugs see limited real-world uptake. The FDA measures adequacy; clinical adoption requires superiority or clear differentiation. Approval risk ends at the FDA; market risk starts there.

    Value Is Relative, Not Absolute

    Value is relative to a decision comparing alternative means. Large changes are transformative; small changes drive marginal behavior. Our model mutes small changes and magnifies large ones — calibrated to human decision-making thresholds.

    Investing Is Science

    Every investment opportunity is a hypothesis. Every investment is an experiment testing, refining, and validating that hypothesis. Every trial and outcome creates knowledge leveraged forward. We put scientific principles first.

    Scoring Formula
    HighEV Raw = Σ(dimension_score × weight) Dimension weights: Functional Value 21% ← outcomes are king Risk Value 18% ← largest variance driver Founder & Team 15% ← execution determines everything Financial Value 12% Effort Value 12% Psychological Value 12% Time Value 10% FDA Adoption Modifier = trial_design × endpoint × guideline × payer_access (range ~0.42× to 1.27×) Final HighEV Score = (Raw / 5) × 100 × FDA Modifier
    Verdict Thresholds

    Below 40 — Pass

    Insufficient NVA. Consider fundamental redesign of value proposition.

    40–59 — Monitor

    Moderate value creation. Niche indications possible. Adoption probability uncertain.

    60–74 — Qualified

    Exceeds Cerdwen threshold. Eligible for deeper diligence and potential investment.

    75+ — High Conviction

    Massively outperforms incumbent. Matches Henry Ford's standard — customers wonder how the company can offer so much.

    Action Tracker

    All deals with a next action — overdue items first.

    Loading actions...
    Settings & Status
    API Connection
    Checking...
    Worker URLhighev-api.piero-automation36.workers.dev
    Databasehighev-db (Cloudflare D1)
    Deals in Pipeline—
    Contacts—
    Export Data

    Download your full pipeline as CSV for Excel, Notion, or LP reporting.

    Slack Alerts
    Active
    Deal → IC Review / InvestedFires immediately
    New partner note addedFires immediately
    Daily digest (overdue actions + new contacts)9:00 AM UTC daily
    Setup: Create a Slack app → Enable Incoming Webhooks → Add to channel → Copy URL, then run:
    echo "https://hooks.slack.com/..." | npx wrangler secret put SLACK_WEBHOOK_URL
    Security
    Session
    Active

    To change your password, run in the highev-worker directory:
    echo "newpassword" | npx wrangler secret put APP_PASSWORD

    HighEV Dimension Weights

    The exact multipliers (summing to 100%) for the Core HighEV score. Modifying these requires a backend redeployment.

    About
    PlatformHighEV Life Sciences Evaluator
    FirmCerdwen Ventures
    FrameworkHighEV (Net Value Add) — Kevin Brophy
    BackendCloudflare Workers + D1
    AI EngineClaude Haiku 4.5 (Anthropic)
    LP & Connection Directory

    Track everyone you meet. Share deal memos directly from here.

    Loading contacts...